Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRMD vs RTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RTX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–4 Matrix Metrics)

RTX Overall Winner 6-Pillar Tally: CRMD 2 – 4 RTX Matrix Metrics: CRMD 4 – 5 RTX

As of Nov 16, 2026, RTX Corporation (RTX) is the stronger overall head-to-head candidate over CorMedix Inc. (CRMD) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CRMD carries a Unified Composite Score of 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin), whereas RTX carries 53.4/100 (HOLD) at $194.95 (24.5x Forward P/E, 13.1% operating margin).

  • Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile RTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 51.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRMD vs RTX
CRMD NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap $384.7M
TTM Revenue $1.05B
Forward P/E 49.0x
Beta / 30D Vol 1.20β · 107% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 60.0 Fund 60.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.2%), weak momentum, RSI 29
RSI-14: 29.3 · SMA20: $6.32 · SMA50: $7.11
RTX NYSE Head-to-Head Winner
RTX Corporation
Aircraft Engines & Engine Parts
$194.95
-1.83% 1D
Market Cap $267.7B
TTM Revenue $96.0B
Forward P/E 24.5x
Beta / 30D Vol 0.28β · 29% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 44.0 Fund 45.0 Flow 55.0 Mom 31.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $196.80 · SMA50: $192.72

6-Pillar Scorecard Institutional Category Breakdown (CRMD 2 – 4 RTX)

Columns: Metric · CRMD · RTX
1. Valuation Multiples RTX
Forward P/E 49.0x 24.5x
Trailing P/E 2.4x 32.2x
PEG Ratio 3.79x 2.15x
EV / Revenue N/M 3.1x
2. Growth & Scale RTX
Revenue Growth (YoY) -47.7% +11.1%
Earnings Growth (YoY) +6.7% +34.0%
TTM Revenue (USD) $1.05B $96.0B
Market Cap $384.7M $267.7B
3. Profitability & Quality CRMD
Gross Margin 87.4% 21.1%
Operating Margin 41.0% 13.1%
Net Profit Margin 15.5% 8.8%
Return on Equity (ROE) 15.3% 12.8%
4. Balance Sheet & Cash Flow CRMD
Cash Generation (TTM) $785M $9.13B
Cash Flow Margin 74.6% 9.5%
Net Cash / Leverage $535M Net Cash $29.7B Net Debt (0.56x D/E)
Dividend Yield None (0.00%) 1.40%
5. Options & Positioning RTX
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 56.3% (25th %ile) 49.8% (67th %ile)
Put/Call OI Skew 0.69x (Call-Skewed) 0.73x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat RTX
OpEx & R&D Intensity 46.4% of Rev ($488M) 8.0% of Rev ($7.68B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Concentrated Oligopoly Moat
Supply-Chain Role Biotechnology Operator Aerospace & Defense Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRMD (4) vs RTX (5)
Institutional Metric CRMD RTX Criterion Row Edge
Market Capitalization
Scale
$384.7M $267.7B Larger Scale RTX
Trailing P/E Ratio
Valuation
2.4x 32.2x Lower Multiple CRMD
Forward P/E Ratio
Valuation
49.0x 24.5x Lower Multiple RTX
Revenue Growth (YoY)
Growth
-47.7% +11.1% Higher Growth RTX
Operating Margin (TTM)
Profitability
41.0% 13.1% Higher Margin CRMD
Net Profit Margin
Profitability
15.5% 8.8% Higher Margin CRMD
Return on Equity (ROE)
Capital Efficiency
15.3% 12.8% Higher ROE CRMD
52-Week Range Position
Momentum
3% ($5–$13) 47% ($167–$227) Stronger Trend RTX
Beta / 30D Volatility
Risk Regime
1.20β · 107% Vol 0.28β · 29% Vol Lower Realized Risk RTX
Unified Institutional Score
Composite Signal
53.2 / 100 (HOLD) 53.4 / 100 (HOLD) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$1.05B $96.0B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.4% 21.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.79x PEG · N/M EV/Rev 2.15x PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$785M ($535M Net Cash) $9.13B ($29.7B Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RTX +32.83 pp
CRMD: -32.3% · RTX: +0.53%
3M Horizon RTX +26.3 pp
CRMD: -39.84% · RTX: -13.54%
6M Horizon RTX +48.66 pp
CRMD: -37.86% · RTX: +10.8%
1Y Horizon RTX +68.23 pp
CRMD: -56.16% · RTX: +12.07%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRMD Revenue RTX Revenue CRMD Op. Margin RTX Op. Margin Margin Leader
FY2018 $0M $34.7B -6250.4% 8.3% RTX
FY2019 $0M $45.4B -7416.3% 10.8% RTX
FY2020 $0M $56.6B -11378.4% -3.3% RTX
FY2021 $0M $64.4B -15417.5% 8.0% RTX
FY2022 $0M $67.1B -46819.9% 8.2% RTX
FY2023 N/A $68.9B N/A 5.2% RTX
FY2024 $40M $80.7B -51.4% 8.1% RTX
FY2025 $310M $88.6B 48.2% 10.5% CRMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRMD BREAKDOWN
109d in phase · OBV DISTRIBUTION
Current IV 56.3%
IV Percentile 25th %ile
Put/Call OI Skew 0.69x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RTX CONSOLIDATION
69d in phase · OBV NEUTRAL
Current IV 49.8%
IV Percentile 67th %ile
Put/Call OI Skew 0.73x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRMD Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $384.7M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment 46.4% of Rev ($488M)
90D Engineering Disclosures 0 Published
RTX Moat Profile Concentrated Oligopoly Moat
Aerospace & Defense Operator
Competes within the Aerospace & Defense value chain with $267.7B market capitalization and 13.1% operating margin.
OpEx & R&D Reinvestment 8.0% of Rev ($7.68B)
90D Engineering Disclosures 0 Published · Drone Autonomy / Counter-UAS

Investor FAQ CRMD vs RTX Key Questions & Quantitative Answers

As of Nov 16, 2026, RTX Corporation (RTX) is the stronger overall head-to-head candidate over CorMedix Inc. (CRMD) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CRMD carries a Unified Composite Score of 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin), whereas RTX carries 53.4/100 (HOLD) at $194.95 (24.5x Forward P/E, 13.1% operating margin). Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile RTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 51.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RTX leads the Growth & Scale pillar: CRMD posts -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin), compared with RTX at +11.1% YoY revenue growth and +34.0% YoY earnings growth on $96.0B TTM revenue (21.1% gross margin, 13.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRMD cumulative revenue shifted +675.0% while RTX shifted +155.3%. In operating R&D and SG&A reinvestment, CRMD deploys 46.4% of Rev ($488M) (0 90-day corporate R&D disclosures) versus 8.0% of Rev ($7.68B) (0 disclosures) for RTX.

RTX screens cheaper on headline valuation multiples. CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin), whereas RTX trades at 24.5x Forward P/E, 32.2x Trailing P/E, 2.15x PEG, and 3.1x EV/Revenue (9.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMD (15.3% ROE) versus RTX (12.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk). By comparison, RTX carries 49.8% implied volatility (67th %ile, Elevated (60th–80th %ile)), a 0.73x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.28β · 29% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.